LILIA AGUILA: Open Payments
NPI 1326698424 · OCALA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,358 in 132 payments from 37 companies in 2025. Trend: 2023 $3,220 · 2024 $3,517 · 2025 $3,358
Food & beverage: $3,188Education: $170
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 22 | $431 |
| AstraZeneca Pharmaceuticals LP | 10 | $329 |
| Incyte Corporation | 7 | $210 |
| Gilead Sciences, Inc. | 9 | $195 |
| Celgene Corporation | 5 | $195 |
| GlaxoSmithKline, LLC. | 10 | $148 |
| Fennec Pharmaceuticals, Inc. | 2 | $130 |
| PFIZER INC. | 6 | $121 |
| Regeneron Healthcare Solutions, Inc. | 4 | $119 |
| Merck Sharp & Dohme LLC | 5 | $105 |
Products named: KISQALI, Trodelvy, REBLOZYL, Fabhalta, LIBTAYO, Pedmark, KEYTRUDA, OJJAARA.
Industry payments across FL — which companies pay providers there.
